• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

TAK-779 Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5758394

TAK-779 is an antagonist of chemokine receptor 5 (CCR5), CCR2b, and CXC chemokine receptor 3 (CXCR3). More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
TAK-779, Inhibitor
Full Product Name
TAK-779
Product Gene Name
Product Synonym Names
Takeda 779
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
531.13
Solubility
DMSO: 25mg/mL (47.07mM)
Ethanol: 62mg/mL (186.5mM)
Water: <1mg/mL
H2O: 16.66mg/mL (31.37mM)
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C33H39ClN2O2
SMILES
Cc1ccc(-c2ccc3c(c2)C=C(C(=O)Nc2ccc(C[N+](C)(C)C4CCOCC4)cc2)CCC3)cc1.[Cl-]
CAS Number
229005-80-5
Target & IC50
Abl: ic50 14nM
Abl (T315I): ic50 4nM
Aurora A: ic50 48nM
FGFR1: ic50 36nM
FLT3: ic50 6.6nM
FLT3 (D835Y): ic50 1nM
JAK2: ic50 150nM
Kit: ic50 300nM
Src: ic50 400nM
MIP-1alpha-CCR5: ic50 1nM (in CHO/CCR5 cells)
MIP-1beta-CCR5: ic50 1nM (in CHO/CCR5 cells)
RANTES-CCR5: ic50 1.4nM (in CHO/CCR5 cells)
MCP-1-CCR2b: ic50 27nM (in CHO/CCR5 cells)
R5 HIV-1 (Ba-L): ic50 3.7nM (EC50, in PBMCs)
R5 HIV-1 (KK): ic50 1.6nM (EC50, in PBMCs)
CCR2
CXCR
Cell Research
Cell viability is determined by the sodium 3'-[1-(phenylaminocarbonyl)-3, 4-tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate assay after incubation with or without KW-2449 for 72 hours at 37 degree C. The number of viable cells is determined using the Cell Proliferation Kit II. For cell-cycle analysis, MOLM-13 and RS4;11 cells are treated with KW-2449. After 24, 48, and 72 hours of incubation at 37 degree C, DNA contents are analyzed. Cell cycle distribution of K562, TCC-Y, and TCC/Ysr is analyzed 24 hours after treatment with KW-2449 or imatinib. (Only for Reference) Cell lines: MOLM-13 and RS4;11 cells
Kinase Assay
FLT3 phosphorylation: Leukemia cells are washed in phosphate-buffered saline (PBS), then lysed by resuspending the cells in lysis buffer (20mM Tris pH 7.4, 100mM NaCl, 1% Igepal, 1mM EDTA, 2mM NaVO4, plus Complete protease inhibitor KW-2449 for 30 minutes while rocking. The extract is clarified by centrifugation at 1.6 × 104g and the supernatant is assayed for protein (Bio-Rad). A 50-ug aliquot is removed as a whole-cell lysate for analysis of STAT5, and the remainder is used for immunoprecipitation with anti-FLT3. Anti-FLT3 antibody is added to the extract for overnight incubation, then protein A sepharose is added for 2 additional hours. Separate sodium dodecyl sulfate-polyacrylamide electrophoresis (SDS-PAGE) gels for whole-cell lysate and immunoprecipates are run in parallel. After transfer to Immobilon membranes, immunoblotting is performed with antiphosphotyrosine antibody (4G10) to detect phosphorylated FLT3 or, for the whole-cell lysate gels, with a rat monoclonal antibody against phosphorylated STAT5 (residue Y694) then stripped and reprobed with anti-FLT3 antibody to measure total FLT3. Proteins are visualized using chemiluminescence, exposed on Kodak BioMax XAR film, developed, and scanned using a Bio-Rad GS800 densitometer. The concentration of KW-2449 for which the phosphorylation of FLT3 or STAT5 is inhibited to 50% of its baseline (IC50) is determined using linear regression analysis of the dose response curves. For direct analysis of FLT3 and STAT5 in circulating blasts, peripheral blood is collected in heparinized tubes and promptly chilled on ice. Samples are centrifuged for 10 minutes at 900 g, at 4 degree C. The plasma is removed and stored frozen at -80 degree C. The buffy coat is carefully transferred to ice-cold PBS, layered onto chilled Ficoll-Hypaque, and centrifuged for 5 minutes at 600 g, at 4 degree C. All subsequent steps are carried out at 4 degree C. Mononuclear cells are collected and washed rapidly once in red blood cell lysis buffer (0.155M NH4Cl, 0.01 M KHCO3, 0.1mM EDTA), then washed once in PBS. Cells are then lysed as described for FLT3 and STAT5 analysis.
In Vitro
TAK-779 increases intestinal allograft survival in a rat model of small intestine transplantation when administered at a dose of 10mg/kg per day[2].

Structure of TAK-779, inhibitor

TAK-779 Inhibitor – Cat# MBS5758394

Product References and Citations for TAK-779, inhibitor

Shiotsu Y, et al. Blood, 2009, 114(8), 1607-17.
Suzaki Y, Hamada K, Nomi T, et al. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation[J]. European Respiratory Journal, 2008, 31(4):783-789.
Suzaki Y, Hamada K, Nomi T, et al. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation[J]. European Respiratory Journal, 2008, 31(4):783-789.
Pratz KW, et al. Blood, 2009, 113(17), 3938-46.
Takama Y, Miyagawa S, Yamamoto A, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model[J]. Transplant Immunology, 2011, 25(1):0-55.
Takama Y, Miyagawa S, Yamamoto A, et al. Effects of a calcineurin inhibitor, FK506, and a CCR5/CXCR3 antagonist, TAK-779, in a rat small intestinal transplantation model[J]. Transplant Immunology, 2011, 25(1):0-55.
Nguyen T, et al. Clin Cancer Res, 2011, 17(10), 3219-32.

Other Notes

Small volumes of TAK-779, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for TAK-779 purchase

MBS5758394 is an inhibitor targeting TAK-779.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000